We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and ... Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. Show more
CTIM-76 IND filing on track for late March 2024 Cash and cash equivalents of $14.4 million as of December 31, 2023 Company expects its cash and cash equivalents will continue to fund operations...
0001842952FALSE00018429522024-02-292024-02-29UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________________FORM 8-K_______________________CURRENT REPORTPursuant to...
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549SCHEDULE 13GUnder the Securities Exchange Act of 1934(Amendment No. 1)*Context Therapeutics Inc.(Name of Issuer)Common Stock...
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations...
FALSE2023Q3000184295212-3100018429522023-01-012023-09-3000018429522023-11-06xbrli:shares00018429522023-09-30iso4217:USD00018429522022-12-31iso4217:USDxbrli:shares00018429522023-07-012023-09-3000018...
0001842952FALSE00018429522023-10-312023-10-31UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_______________________FORM 8-K_______________________CURRENT REPORTPursuant to...
CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated...
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.22 | 18.9655172414 | 1.16 | 1.49 | 1.06 | 148639 | 1.25485471 | CS |
4 | 0.21 | 17.9487179487 | 1.17 | 1.49 | 1.03 | 74851 | 1.19867377 | CS |
12 | 0.2292 | 19.9165797706 | 1.1508 | 1.49 | 0.89 | 45190 | 1.16508762 | CS |
26 | 0.02 | 1.47058823529 | 1.36 | 1.52 | 0.77 | 46273 | 1.15461142 | CS |
52 | 0.77 | 126.229508197 | 0.61 | 1.69 | 0.47 | 74780 | 1.03825531 | CS |
156 | -3.06 | -68.9189189189 | 4.44 | 10.87 | 0.47 | 850453 | 3.94842388 | CS |
260 | -3.06 | -68.9189189189 | 4.44 | 10.87 | 0.47 | 850453 | 3.94842388 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions